Targeted therapy with BRAF inhibitors results in a fast and direct therapy response with rare primary resistance, which is essential in the treatment of patients with rapid tumor progress, high tumor burden, or cerebral metastases [4]. This evidence concerns the gene BRAF and neoplasm.